Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
PURPOSE: Phase I/II trial to study the effectiveness of paclitaxel and radiation therapy plus chemoprotection with amifostine in treating patients with stage III or stage IV head and neck cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
OBJECTIVES:
-
Determine the maximum tolerated dose of paclitaxel with amifostine and radiotherapy in patients with stage III or IV head and neck cancer.
-
Determine the toxic effects and complications of this regimen in terms of mucositis reduction in these patients.
-
Determine the complete response rate and progression-free survival of patients treated with this regimen.
-
Determine whether amifostine modulates the plasma pharmacokinetics of paclitaxel in these patients.
OUTLINE: This is a dose-escalation study of paclitaxel with and without amifostine.
Patients receive paclitaxel IV on days 1, 8, 15, 29, 36, and 43 for a total of 3-6 doses. Patients also undergo radiotherapy twice daily for 6 weeks, except for days when paclitaxel is given.
Cohorts of 2-5 patients receive escalating doses of paclitaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2-3 patients experience dose-limiting toxicity. An additional 10 patients are treated at the MTD.
After determination of the MTD for paclitaxel, subsequent patients also receive amifostine IV over 15 minutes on days 1, 8, 29, and 36 and radiotherapy on days 2-5 and 30-33. Determination of the MTD for this drug combination is carried out as with paclitaxel alone.
At 4 to 8 weeks after the last treatment of radiotherapy, patients undergo CT scanning to determine response. Patients with residual masses undergo neck dissection. Patients with complete or partial response at the primary site are followed without surgery.
Patients are followed every 6 months.
PROJECTED ACCRUAL: A maximum of 37 patients will be accrued for this study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Paclitaxel, amifostine, RT Dose-escalation arm for paclitaxel with amifostine and RT. |
Drug: amifostine trihydrate
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy
|
Outcome Measures
Primary Outcome Measures
- Safety [6 months]
Safety is evaluated in this dose-escalation study
Secondary Outcome Measures
- Response rate [6 months]
Response in terms of CR, PR, stable disease, or progression was determined
Other Outcome Measures
- Survival [5 years]
Percentage of patients alive at 5 years as well as the median overal survival were determined.
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed stage III or IV squamous cell head and neck cancer
-
T3-4, N0-3, M0
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance Status:
- ECOG 0-2
Life Expectancy:
- Not specified
Hematopoietic:
-
WBC at least 2,000/mm^3
-
Platelet count at least 50,000/mm^3
Hepatic:
-
Bilirubin no greater than 3.0 mg/dL
-
SGOT no greater than 3 times upper limit of normal
Renal:
- Creatinine no greater than 3.0 mg/dL
Other:
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Not specified
Endocrine therapy:
- Not specified
Radiotherapy:
- Not specified
Surgery:
- Not specified
Other:
- No concurrent beta-adrenergic blocking agents
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Massachusetts General Hospital Cancer Center | Boston | Massachusetts | United States | 02114 |
2 | Dana-Farber Cancer Institute | Boston | Massachusetts | United States | 02115 |
Sponsors and Collaborators
- Massachusetts General Hospital
Investigators
- Study Chair: Philip C. Amrein, MD, Massachusetts General Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000066028
- MGH-M7-20
- ALZA-97-024-ii
- NCI-V98-1384